ARIAD announces that Iclusig(TM) receives positive CHMP opinion for approval in the European Union
22 March 2013 | By Biosector 2
Positive opinion on the marketing authorization application for Iclusig™...
List view / Grid view
News
CHMP issues positive opinion for TECFIDERA(TM) as a first-line treatment for MS in the European Union
22 March 2013 | By GCI Health
European Commission decision anticipated in second quarter of 2013...
European CHMP adopts positive opinion for Stribild®
22 March 2013 | By Gilead Sciences
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection...
Teva Pharmaceutical’s new investigational treatment for MS
21 March 2013 | By PARADIGM COMMUNICATIONS
TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study...
Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
Sanofi launches 2013 Patient Group Bursary Scheme
21 March 2013 | By Just:: Health PR
2013 Patient Group Bursary Scheme launched...
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
21 March 2013 | By AstraZeneca
AstraZeneca announced that Marc Dunoyer is to join the company...
Takeda launches new subsidiary in Ecuador
21 March 2013 | By Takeda Pharmaceuticals International GmbH (Takeda)
Takeda announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador...
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre
21 March 2013 | By AstraZeneca
The Centre will be set up to conduct preclinical and clinical studies...
AstraZeneca and Moderna Therapeutics announce exclusive agreement
21 March 2013 | By AstraZeneca
Agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer...
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
21 March 2013 | By Novartis
New data presented...
AstraZeneca outlines strategy to return to growth and achieve scientific leadership
21 March 2013 | By AstraZeneca
AstraZeneca will outline its strategy to return to growth and achieve scientific leadership...
3rd Annual Dissolution Symposium on June 3-4 2013
20 March 2013 | By Sirius Analytical Instruments Ltd
The University of Bath, Department of Pharmacy and Sirius Analytical invite you to attend the 3rd Annual Dissolution Symposium...
New data show Azilect® provided clinical benefit in patients with early Parkinson’s
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
Positive year one results from Biogen Idec Phase 3 ADVANCE trial of PLEGRIDY™ presented at AAN Meeting
20 March 2013 | By Biogen Idec
“These full first-year results provide a more complete picture of PLEGRIDY..."
